ARTICLE | Clinical News
Daprodustat: Ph III started
December 1, 2016 11:42 AM UTC
GlaxoSmithKline began the open-label, U.S. Phase III ASCEND-D trial to compare oral daprodustat once daily vs. subcutaneous or IV darbepoetin alfa in about 3,000 dialysis patients switching from an er...
BCIQ Company Profiles
BCIQ Target Profiles